46.5300.26% ( +0.120 )
Closed: Nov 20, 16:00:00 (EDT)Valuation
Current ValuationThe current P/E ratio is -30.18, below the reasonable range, cheaper than 90.64% of the time in the past 5 years, and the industry ranks 210/255, the industry Median -0.87.
-30.18xP/E
$46.53Stock price
$-1.54Earnings per share
-30.18xP/E
Stock price$46.53Earnings per share$-1.54
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -13.27x
- Typical range
- -20.10x–-10.54x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
03468102136
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAYRYUSBayer | -35.48x | -- | $58.98B |
BAYZFUSBayer Aktiengesellschaft | -36.05x | -- | $59.93B |
VTRSUSViatris | -37.03x | 91.33% | $22.50B |
ELANUSElanco Animal Health | -87.52x | 164.80% | $12.87B |
AXSMUSAxsome Therap | -43.26x | 30.77% | $6.80B |
ABVXUSAbivax SA | -13.72x | 22.99% | $6.38B |
CURLFUSCuraleaf Holdings, Inc. | -257.01x | -- | $5.30B |
BLTEUSBelite Bio | -46.24x | 25.00% | $5.13B |
MANEUSVeraDermics | -48.61x | 97.55% | $4.99B |
VREOFUSVIREO GROWTH INC | -76.65x | -- | $4.97B |
LQDAUSLiquidia Tech | -52.07x | 91.61% | $4.90B |
DFTXUSDefinium Therapeutics | -11.50x | 43.16% | $3.88B |
TARSUSTarsus Pharmaceuticals | -5.13x | 879.07% | $3.60B |
ELVNUSEnliven Therapeutics | -30.18x | 5.91% | $3.42B |
AMLXUSAmylyx Pharmaceuticals | -20.50x | 0.72% | $3.35B |
XERSUSXeris Biopharma | -477.28x | -- | $3.10B |
BHCUSBausch Health | -3.66x | 511.90% | $3.08B |
MBXUSMBX Biosciences | -16.45x | 49.14% | $2.39B |
PRGOUSPerrigo | -1.25x | 65.45% | $2.21B |
PHVSUSPharvaris BV | -10.55x | 15.00% | $2.20B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
